Concepedia

Elyse A. Olesinski

EA

Statistics

Publications

4

Citations

263

H-Index

4

Active since

2019

Affiliations

Dana-Farber Cancer Institute(Current)

National University of Singapore

Harvard University

Brigham and Women's Hospital

Broad Institute

Elyse A. Olesinski is an author at Dana-Farber Cancer Institute specializing in life sciences, enzymology, and mitochondrial apoptotic signaling.

ORCID

Publications per year

2019–2024

4

Publications

4

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski et al. · Cancer Cell · 2020 · 174 citations · Full text

, , +16

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

Adam S. Sperling, Michael Burgess, Hasmik Keshishian et al. · Blood · 2019 · 65 citations · Full text

, , +14

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Elyse A. Olesinski, Karanpreet Singh Bhatia, Aarthi N. Mahesh et al. · Blood Advances · 2023 · 14 citations · Full text

, , +11

Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts

Elyse A. Olesinski, Karanpreet Singh Bhatia, Chuqi Wang et al. · Blood Cancer Discovery · 2024 · 10 citations · Full text

, , +17

1–4 of 4